Literature DB >> 19280534

Appropriateness of colonoscopy in Europe (EPAGE II). Iron-deficiency anemia and hematochezia.

I Peytremann-Bridevaux1, C Arditi, F Froehlich, J O'Malley, P Fairclough, O Le Moine, R W Dubois, J-J Gonvers, S Schusselé Filliettaz, J-P Vader, P Juillerat, V Pittet, B Burnand.   

Abstract

BACKGROUND AND STUDY AIMS: To summarize the published literature on assessment of appropriateness of colonoscopy for the investigation of iron-deficiency anemia (IDA) and hematochezia, and report appropriateness criteria developed by an expert panel, the 2008 European Panel on the Appropriateness of Gastrointestinal Endoscopy, EPAGE II.
METHODS: A systematic search of guidelines, systematic reviews and primary studies regarding the evaluation and management of IDA and hematochezia was performed. The RAND/UCLA Appropriateness Method was applied to develop appropriateness criteria for colonoscopy for these conditions.
RESULTS: IDA occurs in 2 %-5 % of adult men and postmenopausal women. Examination of both the upper and lower gastrointestinal tract is recommended in patients with iron deficiency. Colonoscopy for IDA yields one colorectal cancer (CRC) in every 9-13 colonoscopies. Hematochezia is a well-recognized alarm symptom and such patients are likely to be referred for colonoscopy. Colonoscopy is unanimously recommended in patients aged > or = 50. Diverticulosis, vascular ectasias, and ischemic colitis are common causes of acute lower gastrointestinal bleeding (LGIB); CRC is found in 0.2 %-11 % of the colonoscopies performed for LGIB. Most patients with scant hematochezia have an anorectal or a distal source of bleeding. The expert panel considered most clinical indications for colonoscopy as appropriate in the presence of IDA (58 %) or hematochezia (83 %).
CONCLUSION: Despite the limitations of the published studies, guidelines unanimously recommend colonoscopy for the investigation of IDA and hematochezia in patients aged > or = 50 years. These indications were also considered appropriate by EPAGE II, as were indications in patients at low risk for CRC with no obvious cause of bleeding found during adequate previous investigations.

Entities:  

Mesh:

Year:  2009        PMID: 19280534     DOI: 10.1055/s-0028-1119644

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  6 in total

1.  Clinical study of anesthetization by dezocine combined with propofol for indolent colonoscopy.

Authors:  Bin-Bin Xu; Xiao-Liang Zhao; Gui-Ping Xu
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

2.  Colonic involvement in celiac disease and possible implications of the sigmoid mucosa organ culture in its diagnosis.

Authors:  Antonio Picarelli; Marco Di Tola; Raffaele Borghini; Claudia Isonne; Annarita Saponara; Mariacatia Marino; Rossella Casale; Antonio Tiberti; Roberta Pica; Giuseppe Donato; Giuseppe Frieri; Enrico Corazziari
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

Review 3.  Colorectal cancer diagnosis: Pitfalls and opportunities.

Authors:  Pablo Vega; Fátima Valentín; Joaquín Cubiella
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

4.  Young-onset colorectal cancer risk among individuals with iron-deficiency anaemia and haematochezia.

Authors:  Joshua Demb; Lin Liu; Caitlin C Murphy; Chyke A Doubeni; María Elena Martínez; Samir Gupta
Journal:  Gut       Date:  2020-12-18       Impact factor: 31.793

5.  Should asymptomatic young men with iron deficiency anemia necessarily undergo endoscopy?

Authors:  Nam Hee Kim; Jung Ho Park; Dong Il Park; Chong Il Sohn; Kyuyong Choi; Yoon Suk Jung
Journal:  Korean J Intern Med       Date:  2018-01-05       Impact factor: 2.884

6.  A cross-sectional study of the appropriateness of colonoscopy requests in the Spanish region of Catalonia.

Authors:  Diana Puente; Francesc Xavier Cantero; Maria Llagostera; Pilar Piñeiro; Raquel Nieto; Rosa Saladich; Juanjo Mascort; Mercè Marzo; Jesús Almeda; Manel Segarra
Journal:  BMJ Open       Date:  2012-11-30       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.